Clinical Veterinary Boron Neutron Capture Therapy (BNCT) Studies in Dogs with Head and Neck Cancer: Bridging the Gap between Translational and Clinical Studies

Autor: Iara S Santa Cruz, Andrea Monti Hughes, Juan Longhino, S. Nievas, Paulina Oña, Hernan Costa, Marcela A. Garabalino, Andrea Leiras, Sergio Binia, María Silvina Olivera, Emiliano C. C. Pozzi, Lucas Provenzano, Paula Alessandrini, Gustavo A. Santa Cruz, Monica Rao, Esteban Boggio, Verónica A. Trivillin, Amanda E. Schwint, Marı́a de los Angeles Cantarelli, Fabricio Brollo, Sara J. González, Romina Ventimiglia
Rok vydání: 2020
Předmět:
Zdroj: Biology
Biology, Vol 9, Iss 327, p 327 (2020)
Volume 9
Issue 10
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
ISSN: 2079-7737
Popis: Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. The present BNCT studies in veterinary patients with head and neck cancer were performed to optimize the therapeutic efficacy of BNCT, contribute towards exploring the role of BNCT in veterinary medicine, put in place technical aspects for an upcoming clinical trial of BNCT for head and neck cancer at the RA-6 Nuclear Reactor, and assess the feasibility of employing the existing B2 beam to treat large, deep-seated tumors. Five dogs with head and neck cancer with no other therapeutic option were treated with two applications of BNCT mediated by boronophenyl-alanine (BPA) separated by 3&ndash
5 weeks. Two to three portals per BNCT application were used to achieve a potentially therapeutic dose over the tumor without exceeding normal tissue tolerance. Clinical and Computed Tomography results evidenced partial tumor control in all cases, with slight-moderate mucositis, excellent life quality, and prolongation in the survival time estimated at recruitment. These exploratory studies show the potential value of BNCT in veterinary medicine and contribute towards initiating a clinical BNCT trial for head and neck cancer at the RA-6 clinical facility.
Databáze: OpenAIRE